691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

U De Giorgi,B Rosbrook,Q Shen,J Sugg,M Gleave,N Shore,S Sridharan,G.P Haas,S.J Freedland

doi:10.1016/j.annonc.2020.08.2085

691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

U De Giorgi, B Rosbrook + Show 7 more

Open Access

https://doi.org/10.1016/j.annonc.2020.08.2085

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2020
License type: elsevier-specific: oa user license

Affiliation: Pfizer (United States), Astellas Pharma (United States), University of British Columbia, Carolina Urologic Research Center, Calvary Mater Newcastle Hospital

#Enzalutamide Monotherapy #High-risk Nonmetastatic Prostate Cancer + Show 6 more

Abstract
Full-Text PDF
Similar Papers

Abstract

691TiP A phase III, randomized study of enzalutamide (ENZA) plus leuprolide (LHRHa), ENZA monotherapy, and placebo plus LHRHa in men with high-risk nonmetastatic hormone-sensitive prostate cancer (nmHSPC) progressing after local therapy: EMBARK final protocol/study status

Full Text